engleski

Tolerance of Sunitinib in Hemodialysed patients with Metastatic Renal Cell Carcinoma

Patient on hemodialysis can be safely treated with sunitinib in dose of 25-50 mg for 4 weeks with 2 weeks pause. The efficacy of therapy in this patients is similar to non hemodialysed patients. Sunitinib can be prescribed in hemodialysed patients and has no more potential side effects than in non hemodialysed patients.

sunitinib; hemodialysis; metastatic renal cell carcinoma

nije evidentirano